Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)

Figures & data

Table 1. Baseline patient characteristics.

Patient characteristics	Total (N = 198)
Age at baseline (years)
n	198
Mean (SD)	50.0 (14.0)
Gender, n (%)
Male	139 (70.2)
Female	59 (29.8)
Weight, kg
n	137
Mean (SD)	79.9 (13.1)
Body mass index (BMI), kg/m^2
n	136
Mean (SD)	27.3 (4.4)
Severity, n (%)
Moderate*	96 (48.5)
Severe*	102 (51.5)
Psoriasis localization at baseline, n (%)
Face	22 (11.1)
Scalp	53 (26.8)
Palms	34 (17.2)
Soles	27 (13.6)
Nails	14 (7.1)
Genitals	22 (11.1)
Other/not specified localizations	136 (68.7)
Age at diagnosis of psoriasis
n	198
Mean (SD)	35.3 (16.3)
Disease duration (years)
n	198
Mean (SD)	14.7 (13.4)
PASI at baseline
n	193
Mean (SD)	18.6 (7.6)
DLQI at baseline
n	131
Mean (SD)	17.4 (7.3)
Patients with at least one prior psoriasis treatment**, n (%)	179 (90.4)
Bioexperienced	62 (31.3)
Bionaïve	136 (68.7)

*As reported by clinicians in clinical practice; **including conventional systemic, biologics and topical agents. DLQI: Dermatology Life Quality Index; PASI: Psoriasis Area and Severity Index; SD: standard deviation. Percentages were computed on the enrolled population.

Table 2. Proportion of patients achieving PASI 75, PASI 90, and PASI 100.

Response rate (n/N; %; 95% CI)	PASI 75 achievement	PASI 90 achievement	PASI 100 achievement
Week 4	77/116 (66.4%)[CI: 57.8, 75.0]	44/116 (37.9%)[CI: 29.1; 46.8]	32/116 (27.6%)[CI: 19.5; 35.7]
Week 12	151/172 (87.8%)[CI: 82.9; 92.7]	120/172 (69.8%)[CI: 62.9; 76.6]	96/172 (55.8%)[CI: 48.4; 63.2]
Month 6	169/176 (96.0%)[CI: 93.1; 98.9]	150/176 (85.2%)[CI: 80.0; 90.5]	127/176 (72.2%)[CI: 65.5; 78.8]
Month 12	169/177 (95.5%)[CI: 92.4; 98.5]	155/177 (87.6%)[CI: 82.7; 92.4]	133/177 (75.1%)[CI: 68.8; 81.5]
Month 18	166/174 (95.4%)[CI: 92.3; 98.5]	148/174 (85.1%)[CI: 79.8; 90.4]	129/174 (74.1%)[CI: 67.6; 80.6]
Month 24	164/174 (94.3%)[CI: 90.8; 97.7]	148/174 (85.1%)[CI: 79.8; 90.4]	125/174 (71.8%)[CI: 65.2; 78.5]

Proportions were computed on the enrolled population with non missing values.

Figure 1. Line graph of proportions of patients who achieved absolute PASI scores of ≤1, ≤2, ≤3, and ≤5; observed patients. PASI: Psoriasis Area Severity Index. Proportions were computed on the enrolled population with non-missing PASI. Baseline is the baseline visit (i.e., Week 0).

Table 3. Proportion of patients achieving PASI 75, PASI 90, and PASI 100 at various time points; stratified by previous biologics exposure.

Response rate (n/N;%; 95% CI)	PASI 75 achievement	PASI 90 achievement	PASI 100 achievement
Biologic-naïve
Week 4	56/84 (66.7%)[CI: 56.6; 76.8]	30/84 (35.7%)[CI: 25.5; 46.0]	21/84 (25.0%)[CI: 15.7; 34.3]
Week 12	104/115 (90.4%)[CI: 85.1; 95.8]	83/115 (72.2%)[CI: 64.0; 80.4]	65/115 (56.5%)[CI: 47.5; 65.6]
Month 6	114/118 (96.6%)[CI: 93.3; 99.9]	103/118 (87.3%)[CI: 81.3; 93.3]	89/118 (75.4%)[CI: 67.7; 83.2]
Month 12	115/119 (96.6%)[CI: 93.4; 99.9]	106/119 (89.1%)[CI: 83.5; 94.7]	90/119 (75.6%)[CI: 67.9; 83.3]
Month 18	117/122 (95.9%)[CI: 92.4; 99.4]	105/122 (86.1%)[CI: 79.9; 92.2]	92/122 (75.4%)[CI: 67.8; 83.1]
Month 24	113/119 (95.0%)[CI: 91.0; 98.9]	100/119 (84.0%)[CI: 77.5; 90.6]	84/119 (70.6%)[CI: 62.4; 78.8]
Biologic-experienced
Week 4	21/32 (65.6%)[CI: 49.2; 82.1]	14/32 (43.8%)[CI: 26.6; 60.9]	11/32 (34.4%)[CI: 17.9; 50.8]
Week 12	47/57 (82.5%)[CI: 72.6; 92.3]	37/57 (64.9%)[CI: 52.5; 77.3]	31/57 (54.4%)[CI: 41.5; 67.3]
Month 6	55/58 (94.8%)[CI: 89.1; 100.0]	47/58 (81.0%)[CI: 71.0; 91.1]	38/58 (65.5%)[CI: 53.3; 77.8]
Month 12	54/58 (93.1%)[CI: 86.6; 99.6]	49/58 (84.5%)[CI: 75.2; 93.8]	43/58 (74.1%)[CI: 62.9; 85.4]
Month 18	49/52 (94.2%)[CI: 87.9; 100.0]	43/52 (82.7%)[CI: 72.4; 93.0]	37/52 (71.2%)[CI: 58.8; 83.5]
Month 24	51/55 (92.7%)[CI: 85.9; 99.6]	48/55 (87.3%)[CI: 78.5; 96.1]	41/55 (74.6%)[CI: 63.0; 86.1]

Proportions were computed on the enrolled population with non-missing values.

Data availability statement

The data that support the findings of this study are available from the corresponding author, C.B., upon reasonable request.